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It is generally accepted that oxidative stress is involved in HIV infection. However, the role in oxidative balance of Highly Active
Antiretroviral Therapy (HAART) is still debated. In our study we assessed serum oxidant and antioxidant levels in an HIV-
1-infected population treated with HAART, and compared them with those of untreated HIV-1 patients and HIV-1-negative
subjects. The study included 116 HIV-1-infected patients (86 HAART-treated and 30 untreated), and 46 HIV-negative controls.
Serum oxidant levels were signiﬁcantly higher in the HIV-1 treated group as compared to untreated and control groups. In
addition, a decrease of serum total antioxidant status was observed in the HIV-1 treated group. To be noted is that patients who
rigorously follow antiretroviral therapy (optimal HAART adherence) have signiﬁcantly higher oxidative status than those who do
not closely follow the therapy (poor HAART adherence). Analysis of variance revealed no signiﬁcant further increase in oxidative
status in HIV-1-infected patients taking antiretroviral and other drugs with the exception of psychiatric drugs (e.g. anxiolytics
or antidepressants). Taken together, our results indicate that HAART may aﬀect oxidative stress in HIV-1-infected patients and
suggest that antiretroviral therapy plays an important role in the synergy of HIV infection and oxidative stress.
Copyright © 2009 Antonella Mandas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Highly Active Antiretroviral Therapy (HAART) is currently
the therapy of choice for HIV-infected patients [1, 2]. How-
ever, despite remarkable viral replication suppression and
immune response restoration, long-term HAART appears
of limited use in many patients [3], because of additional
adverse eﬀects [4, 5] and/or regimen adherence diﬃculties
[6]. Furthermore, poor adherence to HAART can have seri-
ous consequences, including loss of serum HIV suppression,
development of drug-resistant HIV strains, and increased
probability of illness progression [6]. It is widely reported
that oxidative stress—an imbalance between production and
elimination of chemically reactive species, such as Reactive
Oxygen Species (ROS) [7]—is involved in HIV infection
[8]. Viral Tat protein induces enhanced ROS production
in HIV-infected patients by mitochondrial generation of
superoxide anion [9], which in turn may activate Nuclear
Factor κB( N F - κB) [8], thus increasing HIV transcription.
It has also been found that HIV infection is able to indirectly
inhibitglutathionesynthesis[10],whichisthemainendogen
antioxidant.
HAART may increase chemically reactive species in
circulation,possiblybyproducingmoreoxidizedmetabolites
deriving from the interaction between ROS and infected-
cell biomolecules [11–16]. This is supported by several bio-
chemical mechanisms, such as mitochondrial interference,
followingtreatmentwithHAART-NRTI(NucleosideReverse
Transcriptase Inhibitors) [14–16], and activation of the
P450 hepatic system by HAART, when comprising Protease
Inhibitors (PI) [13]. Insuﬃcient intake or malabsorption of
nutrients—common in HIV patients—may further worsen2 Journal of Biomedicine and Biotechnology
these conditions [17, 18]. It has been suggested that immune
system reactivation may, itself, be a direct cause of oxidative
stress [11] in HAART, when comprising Nonnucleoside
Reverse Transcriptase Inhibitors (NNRTI), such as efavirenz.
Increased levels of serum isoprostane—a class of bioactive
molecules derived from in vivo nonenzymatic oxidation of
arachidonic acid—usually observed in smokers [19, 20],
were also seen in patients taking efavirenz. On the basis of
these ﬁndings, we aimed to assess the eﬀect of HAART on
oxidative stress in an HIV-1-infected population. To do this
we used commercially available tests: (i) d-ROMs test to
assess serum oxidative status and (ii) OXY-Adsorbent test to
assess serum total antioxidant status.
2. Methods
2.1. Subjects. One hundred sixty-two subjects were enrolled
by the Department of Internal Medical Sciences, University
of Cagliari, Italy. Following written informed consent, they
were divided into three groups: (1) HIV-1-negative subjects
(controls), (2) HAART-treated HIV-1-infected patients and
(3) untreated HIV-1-infected patients, as shown in Table 1.
Controls comprised 46 subjects, apparently healthy, on
adequate diets, mean age 39.5 ± 11.4, of whom 21 females.
N oc o n t r o lt o o kd r u g so rn u t r a c e u t i c a l s .T h es e c o n dg r o u p
comprised 86 HIV-1-infected patients, mean age 40.9 ± 8.1,
of whom 39 females, on adequate diets, all treated applying
a therapy plan recommended by international guidelines [2].
One PI and two NRTIs were given to 49 patients: 15 received
PI of nelﬁnavir, 8, lopinavir, 8, indinavir, 5, atazanavir, 5,
saquinavir, 4, amprenavir, and 4, fosamprenavir; all PIs were
boosted, with the exception of nelﬁnavir. One NNRTI and
two NRTI were given to 33 patients: 19 received NNRTI of
nevirapine and 14, efavirenz. Due to therapeutic regimen
failure, the remaining four had to be treated with 1 NRTI
+1N N R T I+1P I .A sN R T It h e r a p yp l a n ,5 1p a t i e n t s
receivedepivir,35,stavudine,30,didanosine,28,zidovudine,
19, tenofovir, and 5, abacavir. The third group comprised 30
HIV-1-infected patients, mean age 35.9 ± 7.9, of whom 14
females, on adequate diets. None of the group took drugs
or nutraceuticals. The treated patients received HAART for
an average of 6.3 ± 2.2 years. Patients taking at least 80%
of their prescribed medication were arbitrarily considered
as having optimal adherence, while those taking under 80%
were considered as having poor adherence. Seventy-one of
the 116 HIV-1-infected patients were smokers (22.5 ± 9.5
cigarettes daily), of whom 14 in the untreated and 57 in the
treated group. There were 20 smokers in the control group
(23.1 ± 9.1 cigarettes daily).
2.2. Oxidative Stress Assessment. Blood samples taken after a
minimum of 12 hours’ fasting were centrifuged and serum
was divided into aliquots and stored at −80◦C until used. To
assess serum total oxidant and antioxidant levels we utilized
the commercially available d-ROMs and OXY-Adsorbent
tests (Diacron International, Grosseto, Italy), respectively
[21, 22]. d-ROMs serum levels of 250–300 CARR U/mL
were considered normal [21, 22], and OXY-Adsorbent serum
levels higher than 350μmoles HClO/mL were considered
normal [22]. These tests were performed according to
manufacturers’ instructions.
2.3. Other Laboratory Assays and Clinical Data. Glycemia,
cholesterolemia, triglyceridemia, alanine aminotransferase
(ALT), HBsAg, anti-HBs, anti-HBc, and anti-HCV antibod-
ies were assessed in all enrolled subjects, using the same
blood samples used in the oxidative status and antioxidant
reef tests. Quantitative serum viral load and blood CD4
T-cells were analyzed in HIV patients. Conventional and
ultrasensitive Roche Amplicore HIV Assay (Roche Molecular
System, Alameda, CA, USA) was used to assess serum HIV
RNA. Viral loads equal or superior to 50 copies/mL serum
can be detected by this test. CD4 T-cells were assessed
by ﬂux cytometry using the IMK multiset commercial kit
(Becton Dickinson, Mountain View, CA, USA). Clinical
data, including smoking habits, Body Mass Index (BMI),
antiretroviral therapy regimen, and HAART adherence, were
collected at the time of laboratory tests.
2.4. Statistical Analysis. Data are expressed as mean ± SD.
In preliminary analyses, we used χ2 tests for nominal vari-
ables and one-way analysis of variance (ANOVA) (Statistic-
StatSoft) for continuous variables, to compare data from the
three groups analyzed. Statistical signiﬁcance levels of at least
P< . 05wereusedforalltests.ToassesstheinﬂuenceofHIV-
RNA on oxidative status, the mean d-ROMs levels of treated
patients with ≤ 400 copies/mL HIV-RNA were compared to
those of treated patients with > 400 copies/mL (ANOVA).
The mean d-ROMs levels of treated patients with ≥ 350/mL
CD4T-cellcountandthoseoftreatedpatientswith<350/mL
CD4 T-cell count were compared (ANOVA), to assess the
inﬂuence of immunological conditions on oxidative status.
To evaluate the inﬂuence of normal and altered levels
of glycemia, ALT, cholesterolemia, and triglyceridemia on
oxidative status, we compared (ANOVA) mean d-ROMs
levelsintreatedpatients withglycemia ≤ 100mg/dLversus>
100mg/dL,ALT≤ 41U/L8versus> 41U/L,cholesterolemia
≤ 180mg/dL versus >180mg/dL, and triglyceridemia ≤
170mg/dL versus > 1 7 0 m g / d L .I no r d e rt or e n d e rr e s u l t s
more evident, we also determined the Odds Ratio (OR) for
the above parameters and multivariate logistic regression for
the clinical and laboratory variables of treated patients.
3. Results
3.1. Clinical Data. The clinical data of the 116 HIV-1-
infected patients (86 HAART-treated and 30 untreated) and
of 46 controls are given in Table 1. As shown, the three
groups diﬀer signiﬁcantly regarding age, number of smokers,
BMI, cholesterolemia, triglyceridemia, and ALT and HIV-
RNA levels.
3.2. Comparisons of Oxidative Balance Markers in HIV-
1 Treated and Untreated Groups and Controls. Oxidative
balance markers for the three experimental groups are
g i v e ni nT a b l e s2 and 3. The number of subjects with
increased d-ROMs (> 300 CARR U/mL) was signiﬁcantly
higher in HIV-1 patients compared to controls (P = .000).Journal of Biomedicine and Biotechnology 3
Table 1: Clinical data of HIV patients and controls.
Controls HIV-1-treated HIV-1-untreated P
Number 46 86 30
Age (years) 39.5 ± 11.4 40.9 ± 8.1 35.9 ± 7.9 .038
∗
Age range 21–61 16–65 21–45
Female/male 21/25 39/47 14/16 .992
∗
Current smokers 20 57 14 .021§
Cigarettes daily 23.1 ± 9.1 25.7 ± 9.8 21.7 ± 9.4 .290
∗
BMI 21.7 ± 1.4 22.8 ± 2.7 23.0 ± 2.2 .017
∗
Cholesterolemia (mg/dL) 183.0 ± 27.4 195.4 ± 39.4 164.7 ± 25.4 .000
∗
Triglyceridemia (mg/dL) 84.7 ± 39.8 181.1± 179.8 90.5 ± 38.9 .000
∗
Glycemia (mg/dL) 88.4 ± 10.3 89.7 ± 19.2 90.5 ± 10.8 .836
∗
ALT (UI/L) 21.1 ± 8.2 46.5 ± 38.9 40.13 ± 36.5 .000
∗
HCV positive 0 39 13
HBV positive 0 1 0
HCV + HDV positive 0 4 1
HAART-PI — 49 —
HAART-NNRTI — 33 —
HAART-PI + NNRTI — 4 —
CD4 T-cell count (cells/mL) nd 554.4 ± 279.2 528.9 ± 119.5 .629
∗
CD4 T-cell count ≥ 500 cells/mL — 46 16 .864§
CD4 T-cell count 499–200 cells/mL — 32 14 .693§
CD4 T-cell count < 200 cells/mL — 8 0 .220§
HIV-RNA level (log10 cp/mL) nd 2.2 ± 0.8 4.1 ± 0.4 .000
∗
HIV-RNA < 400 cp/mL — 69 0
Data are expressed as mean ± SD.
∗Calculated by One-Way ANOVA.
§Calculated by χ2.
As expected, HIV-1-infected patients display higher serum
oxidant levels than controls (P = .000) (Table 2). However,
within the HIV-1-infected group, untreated patients had
signiﬁcantlyloweroxidantlevelsthantreatedones(P = .001,
Table 3). Oxidative status was more pronounced in females
compared to males in all three groups considered. However,
in untreated patients, gender diﬀerence was not statistically
signiﬁcant (P = .08) (Table 3).
The number of subjects with decreased OXY-Adsorbent
(< 350μmol HCLO/mL) was not statistically diﬀerent
among the three groups (Table 2). Treated patients had
antioxidant reef levels signiﬁcantly lower than controls and
untreated patients (P = .000). No signiﬁcant diﬀerence in
antioxidant reef levels was observed in males and females
treated with HAART (P = .59), while control and untreated
males had antioxidant reef levels which were signiﬁcantly
lower than corresponding females (P = .027, P = .018,
resp.).
3.3. Oxidative Balance and Smoking. Smoking is linked to an
increase in oxidative stress [19, 20]. For this reason we next
assessed the inﬂuence of smoking on oxidative balance in the
three experimental groups.
As shown in Table 2, d-ROMs was signiﬁcantly higher
in treated patients—both smokers and nonsmokers—
compared to controls and untreated patients—both smokers
and nonsmokers (P = .000). On the other hand, OXY-
Adsorbent was lower in treated smokers compared to those
in the control and untreated groups (P = .000), while no
diﬀerenceinOXY-Adsorbentwasobservedinnonsmokersin
the three groups (Table 2). As expected, control smokers had
higher d-ROMs levels than control nonsmokers (P = .001).
However, smoking signiﬁcantly aﬀected d-ROMs in neither
treated nor untreated patients (P = .8, P = .2, resp.).
OXY-Adsorbent levels did not diﬀer in smoker and non-
smoker controls (P = .299) nor in smoker and nonsmoker-
untreated patients (P = .841), while they were signiﬁcantly
higher in nonsmoker-treated patients compared to smoker
ones (P = .022).
3.4. Oxidative Status and HAART. Given the high d-ROMs
levels in treated patients, it seemed to us to be of interest
to evaluate the relationship between oxidative status and
HAART adherence. Patients with optimal adherence had
signiﬁcantly higher d-ROMs levels than those with poor
adherence (P = .008; OR = 4.2, 95% C.I. of 1.1–15.5)
(Table 3). Diﬀerences in the following variables CD4 T-cell
count, HIV-RNA level, antiretroviral-drug class, HCV coin-
fection, ALT, glycemia, cholesterolemia, and triglyceridemia
were not signiﬁcantly linked to d-ROMs levels (Table 3).
An additional increase in d-ROMs was observed in patients
receiving HAART plus psychiatric drugs (Table 3).4 Journal of Biomedicine and Biotechnology
Table 2: Comparison of d-ROMs and Oxy-Adsorbent tests between the three groups.
Controls HIV-1 treated HIV-1 untreated P
d-ROMs (CARR U/mL) 295.4 ± 58.9 366.1 ± 68.8 322.1 ± 41.2 .000
∗
d-ROMs (CARR U/mL) in females 319.7 ± 66.6 393.0 ± 78.4 336.3 ± 49.1 .000
∗
d-ROMs (CARR U/mL) in males 275.0 ± 43.1 343.8 ± 50.5 309.6 ± 29.0 .000
∗
d-ROMs increased: no. of subjects 18 72 18 .000§
OXY-Adsorbent (μmol HClO/mL) 433.6 ± 73 411.6 ± 48.2 458.7 ± 50.6 .000
∗
OXY-Adsorbent (μmol HClO/mL) in females 461.1 ± 77.6 408.5 ± 44.3 477.2 ± 57.1 .000
∗
Oxy-Adsorbent (μmol HClO/mL) in males 410.6 ± 61.4 414.1 ± 51.4 430.0 ± 53.5 .228
∗
Oxy-Adsorbent reduced: no. of subjects 4 6 0 .276§
Smokers
d-ROMs (CARR U/mL) 325.9 ± 68.8 362.1 ± 60.4 312.1 ± 30.0 .000
∗
Oxy-Adsorbent (μmol HClO/mL) 420.7 ± 67.3 403.2 ± 45.0 457.6 ± 59.1 .000
∗
Nonsmokers
d-ROMs (CARR U/mL) 272.0 ± 36.6 366.1 ± 56.4 331.4 ± 48.7 .000
∗
Oxy-Adsorbent (μmol HClO/mL) 443.5 ± 76.9 428.1 ± 50.6 453.1 ± 61.8 .113
∗
Data are expressed as mean ± SD.
∗Calculated by One-Way ANOVA.
§Calculated by χ2.
Multivariate logistic regression conﬁrmed signiﬁcant
oxidative-status increase in optimal-adherence-treated
patients (P = .032) and in women (P = .005), while they did
not reveal any link between HAART and psychiatric drugs
(P = .14).
4. Discussion
The d-ROMs and OXY-Adsorbent tests, both available
commercially, were used to determine oxidative status and
antioxidant-reef status, respectively, in the serum of one
treated and one untreated group of HIV-1-infected patients
and of one control group. It has been widely reported
that HIV infection causes oxidative stress [8, 23–25], which
is an imbalance between oxidant and antioxidant status.
Under our experimental conditions, signiﬁcantly higher
d-ROMs levels were found in HIV-1-infected patients—
both treated and untreated—compared to controls, while
OXY-Adsorbent levels were signiﬁcantly reduced in HAART
patients. However, as reported by other authors [26], we
too found that treated HIV-1-infected patients had sig-
niﬁcantly higher d-ROMs levels than untreated ones or
controls. Taken together, our results indicate that HAART
may aﬀect oxidative stress in HIV-1-infected patients and
suggest that antiretroviral therapy plays an important role
in the synergy of HIV infection and oxidative stress [26].
Accordingly, under our experimental conditions, when
treated patients alone are considered, viral load does
not seem to aﬀect oxidative status. Very signiﬁcantly,
patients who rigorously follow antiretroviral therapy (opti-
mal HAART adherence) have higher oxidative status than
those who do not closely follow the therapy (poor HAART
adherence). Diﬀerent therapy regimens do not seem to aﬀect
oxidative status. Analysis of variance revealed no signiﬁ-
cant further increase in oxidative status in HIV-1-infected
patients taking antiretroviral and other drugs (antibiotics,
antihypertensive drugs, painkillers, lipid-lowering agents),
with the exception of psychiatric drugs (e.g., anxiolytics
or antidepressants). However, multivariate logistic regres-
sion analysis conﬁrmed the statistical signiﬁcance of these
ﬁndings for only two variables: optimal HAART adher-
ence and female gender. CD4 T-cell count, HIV-HCV co-
infection, glycemia, cholesterolemia, and triglyceridemia did
not appear to correlate with oxidative status. However,
triglyceridemia and cholesterolemia were signiﬁcantly lower
in controls and untreated patients compared to treated ones,
highlighting the fact that HAART causes dislipidemia [27].
This condition, in turn, may increase the risk of cardio-
vascular disorders. The antioxidant component, assessed
(with the OXY-Adsorbent test) as serum total antioxidant
capacity, was within normal levels (> 350μmol HClO/mL)
in most HIV-1 patients enrolled. This ﬁnding is only
apparently in contrast with literature [17], which reports
reduced antioxidant capacity in HIV-infected patients, pre-
dominantly those at an advanced stage of the illness. In
fact, the pathology status of HIV-1-infected patients under
study, except for 8 treated patients (6.9%) with less than 200
CD4 T-cell/mL, was not yet advanced. It is of interest that
the 30 HIV-1-infected patients who, given their adequate
immunological and virological states, were untreated, had
a higher antioxidant reef than HAART-treated patients.
The lowest antioxidant-reef levels were found in treated
patients, while the highest ones were found in untreated
patients. These ﬁndings are not readily explainable; however,
the lowest antioxidant-reef levels—which were found in
treated patients—might be not only due to the therapy
itself but also due to an increased utilization of endoge-
nous antioxidants, following increased ROS production in
these patients. The remaining important aspects of our
study concern gender and smoking. Oxidative status in
female-treated patients and female controls was signiﬁ-
cantly higher than in males. A possible explanation isJournal of Biomedicine and Biotechnology 5
Table 3: Comparison of d-ROMs concentration in the three groups, dichotomically classiﬁed by clinical and laboratory variables.
Variables d-ROMs P∗ OR (CI 95%)
Controls
Gender Female Male
319.7 ± 66.6 275.0 ± 43.1 .009 6.5 (1.7–24.3)
Smoking Yes No
325.9 ± 68.8 272.0 ± 36.6 .001 6.3 (1.7–23.7)
HIV-1 infection
HAART Yes No
366.1 ± 68.6 322.4 ± 41.5 .001 3.4 (1.3–8.7)
HIV-1 treated
Gender Female Male
393.0 ± 78.4 343.8 ± 50.5 .000 3.7 (0.9–14.2)
Smoking Yes No
362.1 ± 60.4 366.1 ± 56.4 .8 0.7 (0.2–2.6)
CD4 T-cells
≥ 350 cells/mL < 350 cells/mL .6 0.9 (0.2–3.5)
364.0 ± 69.1 373.1 ± 69.0
HIV-RNA
≤ 400cp/mL >400 cp/mL .7 1.1 (0.3–4.6)
364.6 ± 70.1 372.3 ± 64.8
Drug class PI NNRTI
372.5 ± 75.1 359.7 ± 61.6 .4 1.3 (0.4–4.4)
Nelﬁnavir Yes No
398.2 ± 95.6 359.9 ± 61.2 .056 ∞
Nevirapine Yes No
372.3 ± 63.4 364.4 ± 70.6 .7 1.8 (0.4–9.1)
Efavirenz Yes No
348.1 ± 54.2 370.6 ± 71.6 .2 0.4 (0.1–1.5)
HAART adherence Optimal Poor
378.5 ± 71.7 336.0 ± 50.7 .008 4.2 (1.1–15.5)
O t h e rd r u g s+H A A R T Yes No
371.8 ± 61.7 363.1 ± 72.7 .6 2.2 (0.6–8.6)
Psychiatric drugs + HAART Yes No
399.4 ± 51.5 359.7 ± 70.1 .047 ∞
HIV-HCV co-infected Yes No
359.7 ± 57.9 371.3 ± 79.1 .5 1.1 80.3–3.3
ALT
≤ 41 UI/L < 40 UI/L .2 1.0 (0.33–3.3)
374.2 ± 80.8 355.0 ± 46.3
Glycemia
≤ 100 mg/dL < 100 mg/dL .1 2.3 (0.7–8.1)
372.3 ± 71.1 342.9 ± 54.9
Cholesterolemia
≤ 180 mg/dL > 180 mg/dL .2 0.7 (0.2–2.4)
355.0 ± 61.6 372.7 ± 72.5
Triglyceridemia
≤ 170 mg/dL > 170 mg/dL .4 0.8 (0.2–2.8)
371.2 ± 79.4 358.4 ± 48.5
HIV-1 untreated
Gender Female Male
336.3 ± 49.1 309.6 ± 28.9 .076 0.8 (0.2–3.5)
Smoking Yes No
312.1 ± 30.0 331.4 ± 48.7 .2 0.8 (0.2–3.5)
HIV-HCV co-infected Yes No
330.4 ± 38.9 314.7 ± 43.0 .3 2.5 (0.5–11.4)
ALT
≤ 41 UI/L < 40 UI/L .3 0.2 (0.04–1.4)
316.9 ± 40.2 332.4 ± 43.3
Data are expressed as mean ± SD.
∗Calculated by One-Way ANOVA.6 Journal of Biomedicine and Biotechnology
that in these two groups there were several women of
perimenopausal or menopausal age, whose conditions, as
is known, increase ROS production [28, 29]. By contrast,
the majority of untreated female patients under study were
of fertile age and did not signiﬁcantly diﬀer in oxidative
status from males in the same group. Our study, as did
previous ones [19, 20], revealed (as expected) that smoker
controls had a signiﬁcant increase in oxidant levels com-
pared to nonsmoker controls. Surprisingly, no diﬀerence
in oxidative status between treated and untreated HIV-
1-infected groups was seen when, within these groups,
smokers and nonsmokers were compared, even though
the number of smokers in the HIV-1 group was sig-
niﬁcantly higher than in the control group. This result
suggests that increased oxidative stress in HIV-1 patients
mainly depends on the infection and/or antiretroviral
therapy.
5. Conclusion
In summary, our results show that HIV-1 infection increases
oxidative status, and that it is further increased by HAART.
Consequently they suggest that HAART plays an important
role in determining oxidative stress in these patients. Sup-
porting this, patients with optimal adherence show higher
oxidative stress than those with poor adherence. In addition,
they suggest that antiretroviral therapy also aﬀects metabolic
status. Viral load and CD4 do not appear to be involved in
oxidative stress occurring in HIV-1 patients.
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